CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes. [electronic resource]
Producer: 20180524Description: 803-813 p. digitalISSN:- 1440-1711
- Animals
- Antibodies, Blocking -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- CD11a Antigen -- immunology
- Cell Proliferation
- Cytotoxicity, Immunologic
- Diabetes Mellitus, Type 1 -- immunology
- Humans
- Immunotherapy -- methods
- Insulin-Secreting Cells -- immunology
- Intercellular Adhesion Molecule-1 -- immunology
- Interleukin-2 -- immunology
- Killer Cells, Natural -- immunology
- Lymphocyte Activation
- Mice
- Mice, Inbred NOD
- T-Lymphocyte Subsets -- immunology
- T-Lymphocytes, Regulatory -- immunology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.